top of page


ABOUT ADVANCED ACCELERATOR APPLICATIONS
Advanced Accelerator Applications USA, Inc. (AAA), a Novartis company, is developing targeted radioligand therapies and precision imaging radioligands for oncology indications. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA has a legacy as a leader in radiopharmaceutical drugs for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging.
For more information, please visit: www.adacap.com.
Contact a representative:
Laran L. Hyder, MHA
Associate Director, US Patient Advocacy, NET & RST
(617)-413-4296
bottom of page